Figure 2From: Current approaches to the management of Her2-negative metastatic breast cancerTherapeutic approach based on subtype and sensitivity. ER, estrogen receptor; Her2 Neg, Her2-negative; PR, progesterone receptor; Triple Neg, triple-negative.Back to article page